Breaking News: United Therapeutics Corporation Takes Center Stage at the Prestigious Morgan Stanley 21st Annual Global Healthcare Conference!

Exciting News from Silver Spring, MD, and Research Triangle Park, NC! United Therapeutics Corporation (Nasdaq: UTHR), a dynamic public benefit corporation, is set to make waves at the Morgan Stanley 21st Annual Global Healthcare Conference in New York City.

Mark your calendars for Monday, September 11, 2023, because you won’t want to miss this. James Edgemond, the brilliant Chief Financial Officer and Treasurer of United Therapeutics, will take center stage for a captivating fireside chat session. He’ll be sharing an exclusive overview and providing a thrilling update on the company’s thriving business.

The action unfolds from 12:55 p.m. to 1:25 p.m., Eastern Daylight Time, and you’re invited to be part of the excitement.

But don’t worry if you can’t make it in real-time. An archived recording of this electrifying session will be ready for your viewing pleasure approximately 24 hours after the event concludes. Plus, you’ll have a generous 180 days to revisit and relive the insights shared during this extraordinary moment in the world of healthcare and innovation. Stay tuned for a glimpse into the future!

United Therapeutics: Enabling Inspiration

At United Therapeutics, we live and breathe our vision every day, turning it into a vibrant mission. Our secret sauce? A potent mix of enthusiasm, boundless creativity, and unwavering determination that fuels our drive to revolutionize healthcare.

But here’s the twist – we’re not your typical pharmaceutical company. No, we’re bold, we’re unconventional, and yes, we have a blast while doing tremendous good. In fact, we’re pioneers in our own right, proudly bearing the title of the first publicly-traded biotech and pharmaceutical company to adopt the form of a public benefit corporation (PBC).

So, what’s our North Star? It’s twofold: We’re on a mission to create a brighter future for patients by (a) crafting groundbreaking pharmaceutical therapies that shatter the mold and (b) developing cutting-edge technologies that break down barriers to transplantable organs. We’re not just changing the game; we’re redefining it. Join us in this extraordinary journey of innovation and compassion

Forward-Looking Statements

In our journey to shape the future, we’re not just about looking back; we’re all about looking ahead. You’ll find that sprinkled throughout this press release are ‘forward-looking statements,’ and they’re not your typical crystal ball predictions. No, these are bold declarations of our unwavering commitment to innovation, meeting unmet medical needs, and enriching the lives of our patients and stakeholders.

But, as in any adventure, there are twists and turns, and our path is not without its share of risks and uncertainties. We’re not here to sugarcoat it. That’s why we’ve got our diligent scouts meticulously documenting these challenges in our periodic reports filed with the Securities and Exchange Commission. These reports are like our treasure maps, guiding us through the unpredictable terrain.

So, while we’re eager to paint a vivid picture of what’s on the horizon, we must heed the cautionary whispers of our periodic reports and documents filed with the Securities and Exchange Commission, including our trusty Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our ever-vigilant Current Reports on Form 8-K.

But take heart! We’re not in this alone. We’ve got the wind at our backs, thanks to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which shelter our forward-looking statements.

As of September 1, 2023, we’re sharing this glimpse of the future with you, and we’re committed to keeping you in the loop. Whether it’s fresh insights, upcoming events, or unexpected turns, we’ll be here to share the journey – because in our story, every chapter holds the promise of something extraordinary.

Leave a Comment